Expanded Access Program Opens in the U.S. for TLX101-CDx, Telix’s Investigational Glioma (Brain Cancer) Imaging Agent
MELBOURNE, Australia, July 29, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the opening of an expanded access program (EAP) in the United States (U.S.) for TLX101-CDx (Pixclara™1, 18F-floretyrosine …